Evaluation of IGF1/IGFBP3 Molar Ratio as an Effective Tool for Assessing the Safety of Growth Hormone Therapy in Small-for-gestational-age, Growth Hormone-Deficient and Prader-Willi Children

Auteurs Meriem Gaddas Laurence Périn Yves Le Bouc

Published in: Journal of clinical research in pediatric endocrinology (2019)

We consider IGF1/IGFBP3 molar ratio to be a useful additional parameter for assessing therapeutic safety in patients on rGH, and for maintaning the values within the normal range for age and pubertal stage.

Keyphrases

growth hormone
gestational age
end stage renal disease
birth weight
ejection fraction
preterm birth
newly diagnosed
young adults
peritoneal dialysis
prognostic factors
stem cells
physical activity
patient reported outcomes
cell therapy
smoking cessation